Sun Pharma and Lupin receive US FDA approval for divalproex tablets
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industriesand Lupin's US subsidiary have received final approval from the US FDAfor their respective ANDAs for divalproex sodium delayed-release tablets 125mg, 250mg and 500mg, generic versions of Abbott Laboratories' Depakote tablets. Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of complex partial seizures, as sole and adjunct therapy for patients with simple and complex absence seizures, for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches. Both companies expect their products to be on the market shortly. The three strengths of Depakote delayed release tablets reported annual sales of about $750 million in the US.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.